AI Engines For more Details: Perplexity Kagi Labs You
Androgenic Effects: Adrenosterone exhibits weak androgenic activity, meaning it has effects similar to those of other androgens such as testosterone and DHT, although to a lesser extent. Androgens play important roles in the development and maintenance of male reproductive tissues, secondary sexual characteristics, and overall health.
Hormonal Regulation: Adrenosterone is involved in the regulation of various physiological processes, including metabolism, immune function, and cardiovascular health. It interacts with androgen receptors in target tissues, exerting effects on gene expression and cellular function.
Medical Research: Adrenosterone has been investigated in medical research for its potential therapeutic effects in conditions such as adrenal insufficiency, hypogonadism, androgen deficiency syndromes, and certain dermatological conditions. However, its clinical use as a prescription medication is limited compared to other androgens.
Adrenal Function: Adrenosterone is synthesized in the adrenal cortex, particularly in the zona reticularis, which is the innermost layer of the adrenal cortex. It is produced from dehydroepiandrosterone (DHEA) through enzymatic conversion by 11Ξ²-hydroxysteroid dehydrogenase type 1 (11Ξ²-HSD1) and 11Ξ²-hydroxylase.
Role in Hormone Pathways: Adrenosterone is a precursor to testosterone and DHT in the androgen biosynthesis pathway. It can be converted to testosterone through the action of enzymes such as 17Ξ²-hydroxysteroid dehydrogenase (17Ξ²-HSD) and 3Ξ²-hydroxysteroid dehydrogenase (3Ξ²-HSD) in peripheral tissues.
Potential Therapeutic Uses: While adrenosterone itself is not commonly used as a prescription medication, its derivatives or metabolites may have therapeutic potential in certain conditions. For example, synthetic analogs of adrenosterone have been investigated for their anti-inflammatory, immunomodulatory, and dermatological effects.
Side Effects and Risks: Like other androgens, adrenosterone may have potential side effects and risks, particularly when used in high doses or for prolonged periods. These may include masculinization (in females), virilization (in children), acne, alopecia (hair loss), mood changes, and alterations in lipid metabolism.
Regulatory Status: The regulatory status of adrenosterone and its derivatives may vary depending on the country and jurisdiction. In some cases, they may be classified as controlled substances or subject to restrictions due to their androgenic properties and potential for abuse.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.4 | 0.1 | 3 |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.7 | -0.75 |
Allergies | 1.5 | 1 | 0.5 |
Allergy to milk products | 0.9 | 0.3 | 2 |
Alzheimer's disease | 1.2 | 1.1 | 0.09 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.8 | 0 |
Ankylosing spondylitis | 1.5 | 0.5 | 2 |
Anorexia Nervosa | 0.2 | 0.4 | -1 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 1 | 0.1 | 9 |
Atherosclerosis | 1 | 1 | |
Atrial fibrillation | 0.4 | 0.8 | -1 |
Autism | 1.6 | 2.3 | -0.44 |
Autoimmune Disease | 0.5 | 0.5 | |
Barrett esophagus cancer | 0.2 | 0 | 0 |
benign prostatic hyperplasia | 0.5 | 0 | 0 |
Biofilm | 1 | 1 | |
Bipolar Disorder | 0.8 | 0.3 | 1.67 |
Brain Trauma | 0 | 0.2 | 0 |
Breast Cancer | 0.9 | 0.9 | |
Cancer (General) | 0.2 | 0.1 | 1 |
Carcinoma | 1.1 | 0.2 | 4.5 |
Celiac Disease | 0.8 | 0.3 | 1.67 |
Cerebral Palsy | 0.1 | 0.2 | -1 |
Chronic Fatigue Syndrome | 1.7 | 0.7 | 1.43 |
Chronic Kidney Disease | 0.7 | 0.3 | 1.33 |
Chronic Lyme | 0 | 0 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.4 | 1.25 |
Chronic Urticaria (Hives) | 0.9 | 0.3 | 2 |
Coagulation / Micro clot triggering bacteria | 1.1 | 0.2 | 4.5 |
Cognitive Function | 0.3 | 0 | 0 |
Colorectal Cancer | 2.4 | 0.7 | 2.43 |
Constipation | 0.9 | 0.9 | |
Coronary artery disease | 1.3 | 0.1 | 12 |
COVID-19 | 1.8 | 1.5 | 0.2 |
Crohn's Disease | 2.3 | 0.8 | 1.87 |
Cushing's Syndrome (hypercortisolism) | 0.2 | -0.2 | |
cystic fibrosis | 0.9 | 0 | 0 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 1.5 | 0.3 | 4 |
Denture Wearers Oral Shifts | 0.3 | 0.3 | |
Depression | 2.2 | 1.2 | 0.83 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.7 | 0 | 0 |
Endometriosis | 1.2 | 1 | 0.2 |
Eosinophilic Esophagitis | 0.2 | 0 | 0 |
Epilepsy | 1.3 | 0 | 0 |
erectile dysfunction | 0.7 | 0.7 | |
Fibromyalgia | 0.1 | 0.4 | -3 |
Functional constipation / chronic idiopathic constipation | 1.7 | 0.7 | 1.43 |
gallstone disease (gsd) | 1.1 | 0.2 | 4.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.1 | 5 |
Generalized anxiety disorder | 1.4 | 0.1 | 13 |
Glioblastoma | 0 | 0 | |
Gout | 0.3 | 0.3 | 0 |
Graves' disease | 0.2 | 0.3 | -0.5 |
Gulf War Syndrome | 0.1 | 0.1 | |
Halitosis | 0.5 | 0 | 0 |
Hashimoto's thyroiditis | 0.5 | 0.2 | 1.5 |
Heart Failure | 1.9 | 0.2 | 8.5 |
hemorrhagic stroke | 0.2 | 0.2 | |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
High Histamine/low DAO | 0.6 | 0.2 | 2 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
hyperglycemia | 1.1 | 0 | 0 |
hypertension (High Blood Pressure | 0.9 | 0.5 | 0.8 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0.5 | 0.5 | 0 |
Inflammatory Bowel Disease | 2.4 | 1.9 | 0.26 |
Insomnia | 0.1 | 0.4 | -3 |
Intelligence | 0.7 | 0.3 | 1.33 |
Intracranial aneurysms | 0.4 | 0.1 | 3 |
Irritable Bowel Syndrome | 1.7 | 0.6 | 1.83 |
ischemic stroke | 0.9 | 0.5 | 0.8 |
Liver Cirrhosis | 1.4 | 1.1 | 0.27 |
Long COVID | 1 | 1.2 | -0.2 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.5 | 0.2 | 1.5 |
Lymphoma | 0.5 | 0.5 | |
Mast Cell Issues / mastitis | 0.8 | 0.3 | 1.67 |
ME/CFS with IBS | 0 | 0.2 | 0 |
ME/CFS without IBS | 0.2 | 0 | 0 |
membranous nephropathy | 0 | 0 | |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 1.6 | 0.6 | 1.67 |
Mood Disorders | 1.4 | 1.3 | 0.08 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 1.3 | 0.8 | 0.63 |
Multiple system atrophy (MSA) | 0.1 | 0.2 | -1 |
myasthenia gravis | 0.5 | 0.5 | |
neuropathic pain | 0.1 | 0.1 | 0 |
Neuropathy (all types) | 0.1 | 0.3 | -2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 0.4 | 3.75 |
NonCeliac Gluten Sensitivity | 0.1 | 0 | 0 |
Obesity | 2 | 1.1 | 0.82 |
obsessive-compulsive disorder | 1.6 | 0.5 | 2.2 |
Osteoarthritis | 0.4 | 0.3 | 0.33 |
Osteoporosis | 0.8 | 0.1 | 7 |
pancreatic cancer | 0.3 | 0 | 0 |
Parkinson's Disease | 1.8 | 1.2 | 0.5 |
Polycystic ovary syndrome | 1.5 | 0.7 | 1.14 |
Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
primary biliary cholangitis | 0 | 0.2 | 0 |
Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
Psoriasis | 0.8 | 0.4 | 1 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.3 | 5.67 |
Rosacea | 0.3 | 0.3 | |
Schizophrenia | 0.6 | 0.4 | 0.5 |
scoliosis | 0.7 | 0.4 | 0.75 |
Sjögren syndrome | 0.8 | 0 | 0 |
Sleep Apnea | 0.6 | 0.2 | 2 |
Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
Stress / posttraumatic stress disorder | 1 | 0.2 | 4 |
Systemic Lupus Erythematosus | 0.8 | 0.3 | 1.67 |
Tic Disorder | 0.4 | 0.3 | 0.33 |
Tourette syndrome | 0 | 0 | 0 |
Type 1 Diabetes | 1 | 0.5 | 1 |
Type 2 Diabetes | 1.8 | 1.3 | 0.38 |
Ulcerative colitis | 1.7 | 0.7 | 1.43 |
Unhealthy Ageing | 0.9 | 0.1 | 8 |
Vitiligo | 0.4 | 0.2 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]